Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Matthew Bujold"'
Autor:
Yali Song, Alessandra Franco, Adriana H. Tremoulet, Matthew Bujold, Jane C. Burns, John T. Kanegaye, Chisato Shimizu
Publikováno v:
Burns, JC; Song, Y; Bujold, M; Shimizu, C; Kanegaye, JT; Tremoulet, AH; et al.(2013). Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. Clinical and Experimental Immunology, 174(3), 337-344. doi: 10.1111/cei.12182. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/4ng835m2
Clinical and experimental immunology, vol 174, iss 3
Clinical and experimental immunology, vol 174, iss 3
Summary The expansion of regulatory T cells (Treg) controls inflammation in children with acute Kawasaki disease (KD). Blockade of tumour necrosis factor (TNF)-α is an emerging therapy for KD patients with refractory inflammation, but there is conce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64fa7ff9471d6adcdac30eb6caf68361
http://www.escholarship.org/uc/item/4ng835m2
http://www.escholarship.org/uc/item/4ng835m2
Autor:
Matthew Bujold, Daniel M. Appledorn, Yasser A. Aldhamen, William Nance, Sarah Godbehere, Nathaniel J. Schuldt, Tyler Voss, Andrea Amalfitano, Sergey S. Seregin, Aaron J. Mcbride, Junping Wei
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy. 17(4)
More than 300 human clinical trials utilize recombinant adenoviruses (rAds) as a gene transfer vector, confirming that rAds continue to be of high clinical interest. A primary weakness of rAds is their known propensity to trigger an innate, proinflam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b4d48908d8a6328981e4483a0552e9f
https://pubmed.ncbi.nlm.nih.gov/19174760
https://pubmed.ncbi.nlm.nih.gov/19174760
Autor:
Matthew Bujold, Alyson Tamamoto, Yoshihiro Onouchi, Alessandra Franco, Guliz Erdem, Jane C. Burns, Debra A. Dodd, Chisato Shimizu, Paige Pancoast, Adriana H. Tremoulet
Publikováno v:
The Journal of Pediatrics. 161:506-512.e1
Objective To describe the clinical course and outcome of 10 patients with Kawasaki disease (KD) treated with a calcineurin inhibitor after failing to respond to multiple therapies. Study design Demographic and clinical data were prospectively collect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::372a7246199fe4bbc056879ad0119fa4
https://doi.org/10.1016/j.jpeds.2012.02.048
https://doi.org/10.1016/j.jpeds.2012.02.048